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ORIGINAL ARTICLE
Chronic intrahypothalamic rather than subcutaneous
liraglutide treatment reduces body weight gain and stimulates
the melanocortin receptor system
K Kaineder1, T Birngruber2, G Rauter3, B Obermüller3, J Eichler4, J Münzker1, W Al-Zoughbi5, SI Mautner2, SS Torekov6, B Hartmann6,
P Kotzbeck1 and TR Pieber1,2
BACKGROUND: The GLP-1 receptor agonist liraglutide is marketed for obesity treatment where it induces body weight reduction
possibly via the hypothalamus, which regulates energy homeostasis. In animal studies, acute liraglutide treatment triggers satiety,
weight loss and activates thermogenesis in adipose tissue. However, the precise mechanisms how liraglutide affects in particular
chronic weight loss are still under investigation.
OBJECTIVES: We aimed to evaluate whether chronic hypothalamic or chronic subcutaneous administration of liraglutide induces
sustained weight loss through altered adipose tissue function and to what extent hypothalamic neuronal appetite regulators are
involved in the liraglutide-induced weight loss in healthy lean rats on a normal diet.
MATERIALS/METHODS: We continuously administered liraglutide either intrahypothalamically (10 μg per day) or subcutaneously
(200 μg kg− 1 per day) for 28 days to lean Sprague Dawley rats (n= 8 each). We assessed changes in body weight, adipose tissue
mass, adipocyte size and adipose tissue volume in the abdominal region by using micro-CT. We analyzed genetic expression
patterns of browning, thermogenic and adipocyte differentiation regulators in adipose tissues as well as particular neuronal
appetite regulators in the hypothalamus.
RESULTS: Intrahypothalamic liraglutide administration induced an 8% body weight reduction at day 9 compared with the control
group (Po0.01) and a 7% body weight loss at day 9 compared with subcutaneous liraglutide treatment (Po0.01), supported by a
significant reduction in adipose tissue mass and volume with intrahypothalamic liraglutide administration (Po0.05). Our data show
that chronic intrahypothalamic liraglutide treatment triggered an 18-fold induction of the hypothalamic mc4r gene (Po0.01)
accompanied by a significant increase in circulating thyroxine (T4) levels (Po0.05).
CONCLUSIONS: Chronic intrahypothalamic liraglutide administration resulted in a profound reduction in body weight and fat mass
loss most likely mediated by the hypothalamic melanocortin system rather than by adipose tissue browning or improved
thermogenesis.
International Journal of Obesity (2017) 41, 1263–1270; doi:10.1038/ijo.2017.98
INTRODUCTION
Liraglutide is a long-acting GLP-1 receptor (GLP-1R) agonist and
has been FDA and EMA approved for the treatment of obesity.1
Liraglutide lowers blood glucose levels by stimulating insulin
secretion and by inhibiting glucagon secretion in a glucose-
dependent manner.2 In addition to its glucoregulatory effects,
liraglutide reduces caloric intake and subsequently leads to
sustained but moderate weight loss.3 The glucoregulatory
mechanisms of liraglutide are well known, but the mediating
mechanisms underlying the anorectic and body weight-reducing
effects are less clear.4 Acute central liraglutide treatment (24 h,
ventromedial hypothalamic nucleus) in rodents has been shown
to result in body weight loss independent of caloric intake. Body
weight loss was attributed to the stimulation of thermogenesis in
the brown adipose tissue (BAT) and browning of white adipose
tissue (WAT) via the hypothalamic AMP-activated protein kinase
pathway.5 Peripheral liraglutide administration led to a reduced
ability to suppress food intake and maintain body weight in diet-
induced obese mice with a GLP-1 receptor knockdown in the
central nervous system.6 In addition, peripheral liraglutide
administration in rats with pharmacological antagonized GLP-1
receptors in the brain resulted in a reduced ability to suppress
food intake.7 A recent study more specifically identified POMC/
CART neurons in the arcuate nucleus of the hypothalamus as the
main mediators of weight-reducing effects after chronic peripheral
liraglutide treatment.8 But peripheral administration of liraglutide
often leads to only limited effects mediated in the brain because
only small amounts of the large liraglutide–albumin complex can
cross the blood–brain barrier.4 In humans, such a limited passive
transport of peripherally administered liraglutide to the cere-
brospinal fluid did not correlate with the observed weight loss.9
Combining the existing data, acute pharmacological interven-
tions do not necessarily reflect the physiological, chronic
regulation of feeding by the brain. A direct comparison of chronic
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central and chronic peripheral liraglutide administration in a single
study would help to link existing studies investigating either
central or peripheral administration. Such comparative data on
chronic central and peripheral effects of liraglutide are necessary
to identify new pathways to improve the pharmacological benefits
of chronic obesity treatment.
We aimed to evaluate whether chronic hypothalamic or chronic
subcutaneous administration of liraglutide induces sustained
weight loss through altered adipose tissue function and to what
extent hypothalamic neuronal appetite regulators are involved in
the liraglutide-induced weight loss.
MATERIALS AND METHODS
Animal models
Male Sprague Dawley rats (12–15 weeks old and weight matched; Charles
River Laboratories, Sulzfeld, Germany) were housed under conditions of
controlled temperature (23 °C) and a 12 h light/dark cycle. The rats had ad
libitum access to water and standard laboratory diet. Immediately after the
rats were killed by rapid decapitation, tissue samples (hypothalamus,
brown and white adipose tissue) were removed, frozen in liquid nitrogen
and kept at − 80 °C until further analysis. All animal experiments were
approved by the Austrian Federal Government (BMWF-66.010/0010-WF/V/
3b/2015) and were performed in accordance with Directive 2010/63/EU on
the protection of animals used for scientific purposes.
Study design
The study design (non-blinded) was based on four groups (each n= 8). Two
groups received treatment (liraglutide) either intrahypothalamically
(central) or subcutaneously (peripheral) and two groups received placebo
(artificial cerebrospinal fluid (aCSF) or 0.9% NaCl) again either intrahy-
pothalamically or subcutaneously. Group 1: intrahypothalamic liraglutide;
group 2: intrahypothalamic vehicle (aCSF); group 3: subcutaneous
liraglutide; group 4: subcutaneous vehicle (NaCl). Group 2 and group 4
(treated with placebo) served as control groups.
To determine the acute (24 h) effects of liraglutide on body weight,
adipose tissue mass and gene expression patterns (hypothalamus, WAT
and BAT), liraglutide (10 μg per animal) or aCSF (2 μl) were injected just
above the dorsal part of the paraventricular nucleus (stereotactic
coordinates: anteroposterior: 1.7 mm, mediolateral: 0.6 mm, dorsoventral:
7.6 mm). For chronic administration, the rats were continuously treated for
28 days with either 10 μg per day per animal intrahypothalamic liraglutide
or with 200 μg kg− 1 per day subcutaneous liraglutide via osmotic pumps.
The administered dose of intrahypothalamic liraglutide was chosen on its
ability to significantly inhibit feeding and induce body weight loss.10,11 The
dose of subcutaneous administration was chosen to differentiate between
the effect of peripheral (subcutaneous) and central (intrahypothalamic)
liraglutide.8
Implantation of osmotic pumps
Before implantation, rats were individually placed in an anesthesia
induction chamber (Rothacher, Heitenried, Switzerland) induced with 4
vol% isoflurane (Isoflo, Esteve Farma, Carnaxide, Portugal) in 100% oxygen
with a delivery rate of 5 l min− 1 until loss of righting reflex. The rats were
anesthetized using 0.1 ml kg− 1 of an injectable anesthetic (0.5 mg kg− 1
midazolam, 5 μg kg− 1 fentanyl, 5 mg kg− 1 medetomidin; 1 ml per 1 kg
body weight, ERWO Pharma GmbH, hameln pharma plus GmbH, Vienna,
Austria). Anesthesia was maintained with isoflurane in 100% oxygen at a
flow of 1.5 l min− 1. For 28 days continuous drug administration, we chose
the pump models 2ML4 (1997.2 μl fill volume, 2.55 μl h− 1 flow rate) for
subcutaneous and the model 2004 (234 μl fill volume, 0.22 μl h− 1 flow
rate) for intrahypothalamic administration (ALZET Durect, Cupertino, CA,
USA). Osmotic pumps were implanted according to the manufacturer’s
instructions by creating a pocket at the midscapular region using a
hemostat and inserting the filled pump in the pocket.
Implantation of intrahypothalamic cannula
The induction of anesthesia for stereotactic surgery was the same as for
the implantation of osmotic pumps as described above. Stereotactic
surgery and postsurgical pain control was performed as previously
described.12 The brain cannula (PlasticsOne, Bilaney Consultants,
Düsseldorf, Germany) was implanted just above the dorsal part of the
paraventricular nucleus (stereotactic coordinates: anteroposterior: 1.7 mm,
mediolateral: 0.6 mm, dorsoventral: 7.6 mm). For intrahypothalamic
administration, the cannula was connected to the osmotic pump that
was filled with liraglutide (1.91 μg h− 1; Novo Nordisk, Bagsværd, Denmark)
dissolved in aCSF (Harvard Apparatus, March-Hugstetten, Germany). The
coordinates were histologically verified after injection of 1% Evans Blue
dye and spectrophotometrically by analyzing sodium fluorescein dye in
hypothalamic tissues (Supplementary Material).
Assessment of body weight, adipose tissue mass and size
Body weight was continuously assessed on a precise laboratory scale
(Competence CP3202S-0CE, Sartorius AG, Göttingen, Germany). After
28 days, the rats were killed and freshly excised adipose tissues depots
(inguinal WAT, epididymal WAT, interscapular BAT) were weighed on an
analytical balance (M-Power AZ214, Sartorius AG, Göttingen, Germany).
Epididymal (eWAT) and inguinal (iWAT) white adipose tissue and
interscapular brown adipose tissue (iBAT) were isolated, fixed in 4%
paraformaldehyde overnight at room temperature and embedded in
paraffin. The embedded tissues were cut in 5 μm-thick sections and
stained with hematoxylin and eosin. The adipose tissue sections were
evaluated using the Olympus BX51 microscope and representative areas
from these sections were captured by using the Olympus camera 4A14690.
The images were acquired with a standard × 20 microscope objective lens.
The imaging area was selected according to a high prevalence of
adipocytes with an intact cell membrane and minimal adjacent tissues
such as blood vessels, muscle and inflammatory cells. Adipocytes with
unclear cell borders were excluded from the analysis. Image annotation
was performed manually by using the Olympus analySIS five software and
the mean adipocyte size was calculated for each type of adipose tissue.
Assessment of visceral and subcutaneous adipose tissue volume
Abdominal adipose tissue volumes of visceral and subcutaneous depots
were measured with a micro-CT scanner (Siemens Inveon micro-CT,
Siemens Healthcare GmbH, Erlangen, Germany; energy settings: 200 mA,
80 kV, 1200 ms) with Siemens Inveon Acquisition Workplace software
(version 1.2.2.2) before (baseline) drug treatment and after 28 days of
chronic infusion of liraglutide or vehicle. Data were reconstructed using
filtered back projection and algorithm of Feldkamp in Siemens Inveon
Acquisition workplace. The reconstructed data sets were exported to
DICOM format using Siemens Inveon Research Workplace and post
processed regarding adipose tissue volumes using Materialise MIMICS v.19
(Materialise, Leuven, Belgium). We focused on the abdominal region, as
scanning the abdominal adipose depots provides sufficient information to
estimate the total body fat and monitor site-specific changes in adiposity
and reduces scanning time.13
RNA isolation, complementary DNA transcription and reverse
transcribed-quantitative PCR
QIAzol Lysis Reagent (QIAGEN GmbH, Hilden, Germany) was used for tissue
lysis. The total RNA content was isolated from homogenized adipose and
hypothalamic tissue by using the RNeasy Mini Kit (QIAGEN GmbH, Hilden,
Germany) including on-column DNaseI treatment. RNA quantity was
measured on NanoDrop (NanoDrop 2000c, ThermoFisherScientific GmbH,
Vienna, Austria) and 1 μg total RNA was reverse transcribed to cDNA by
using the iScript advanced cDNA synthesis kit (Bio-Rad Laboratories,
Vienna, Austria). Gene expression analysis via quantitative PCR was
performed using TaqMan Universal PCR Master Mix (Life Technologies,
Carlsbad, CA, USA) or LightCycler 480 SYBR Green I Master Mix (Roche,
Vienna, Austria) according to the manufacturer’s instructions on a Roche
LightCycler 480 Instrument (Roche Austria, Vienna, Austria). The sequences
of primers and probes are listed in the Supplementary Material.
Measurement of metabolic and hormonal parameters
Plasma glucose levels were assessed by using the Accu-Check Performa
system (Roche Diabetes Care Austria GmbH, Vienna, Austria). Non-
esterified free fatty acids (NEFA) were measured via the enzymatic
colorimetric NEFA-HR(2) assay kit (WAKO Diagnostics, Richmond, VA, USA).
Plasma-free glycerol content was colorimetrically quantified using free
glycerol reagent (Sigma Aldrich, Vienna, Austria). Plasma triglyceride
concentrations were analyzed by using the Infinity Triglyceride Assay
(ThermoScientific, Vienna, Austria). Circulating leptin, insulin, thyridiodine
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(T3) and thyroxine (T4) concentrations were measured with the Mesoscale
Multiplex Array Elisa System (Mesoscale Diagnostics, Rockville, MD, USA).
All the measurements were performed according to the manufacturer’s
instructions.
Statistical analysis
The data are expressed as mean± s.d. compared with the corresponding
control or treatment group. The sample size was chosen based on
published literature and to perform descriptive statistics. Shapiro–Wilk test
was used to scrutinize normality. Either unpaired Student's two-tailed t-test
or Mann–Whitney U-test were used to determine statistical significance of
data comparing the two groups. Subsequently, the P-values were
corrected for multiple testing using the Benjamini–Hochberg procedure.
To determine equality of variances between and within subjects, Levene’s
and Mauchley’s sphericity tests with Greenhouse–Geisser correction were
used. For repeated body weight measurements, we used two-way
repeated-measures mixed-model analysis of variance plus Bonferroni post
hoc analysis. The corrected P-values o0.05 were considered statistically
significant. The calculations were performed in GraphPad Prism Mac 5.0b
software (La Jolla, CA, USA) and SPSS Statistics 23 (IBM, Ehningen,
Germany). Relative gene expression levels (messenger RNA (mRNA)) were
analyzed using the 2(−ΔΔCt) method.14
RESULTS
Central chronic liraglutide treatment reduces body weight gain
and promotes adipose tissue mass reduction
Intrahypothalamic treatment resulted in a significant body weight
loss of 4% at day 7 (Po0.05) and 5% at day 9 (Po0.05) compared
with baseline. Compared with the control group (intrahypotha-
lamic vehicle), chronic intrahypothalamic liraglutide treatment
significantly reduced body weight gain by 6% at day 7 (Po0.05),
8% at day 9 (Po0.01), 6% at day 14 and day 16 (Po0.05;
Figure 1a). A 3% reduction in body weight gain was maintained
from day 21 to day 28 compared with intrahypothalamic control
group (Figure 1a). Intrahypothalamic liraglutide-treated rats had
significantly reduced epididymal and inguinal fat mass compared
with the control group (Po0.05; Figure 1b). Chronic peripheral
(subcutaneous) administration of liraglutide did neither affect
body weight (Figure 1c), nor did it reduce adipose tissue mass
(Figure 1d). Compared with the subcutaneous liraglutide treat-
ment group, chronic intrahypothalamic liraglutide treatment
induced a significant body weight loss at day 9 (Po0.001), at
day 14 and 16 (Po0.01), at day 23 and 28 (Po0.05; Figure 1e).
Intrahypothalamic liraglutide treatment resulted in a significant
reduction of inguinal white and interscapular brown adipose
tissue compared with subcutaneous liraglutide treatment
(Po0.01; Figure 1f).
Central chronic liraglutide treatment reduces brown adipocyte
size
Brown adipocytes were significantly smaller with chronic intrahy-
pothalamic liraglutide administration compared with the control
group (Po0.05; Figures 2a and b). We found a trend towards
reduced adipocyte size in eWAT and iWAT (Figure 2a).
Central chronic liraglutide treatment reduces visceral adipose
tissue gain
After 28 days of intrahypothalamic liraglutide treatment, we found
a significant decrease of visceral adipose tissue compared with
the control group (Po0.05; Figure 3a). The subcutaneous adi-
pose tissue volume showed a trend towards reduced adipose
tissue volume gain by intrahypothalamic liraglutide treatment
(Figure 3b) compared with intrahypothalamic vehicle group.
The liraglutide-induced reduction in body weight and adipose
tissue mass is independent of thermogenesis or browning of
adipose tissue
Chronic intrahypothalamic liraglutide treatment did not affect
expression of brown adipocyte marker (ucp1), and expression of
browning and adipogenesis markers (prdm16, cidea, fgf21, tnfrsf9,
zic1, bmp7, cebpb, ppargc1a, pparg) in iWAT, eWAT and iBAT
(Figure 4). Mitochondrial cytochrome c oxidase subunit 3 (mtco3)
in eWAT was significantly increased with intrahypothalamic
liraglutide administration compared with the control group
(Po0.05; Figure 4a). We observed a trend towards reduction of
leptin and lipoprotein lipase (lpl) mRNA levels in eWAT and iWAT
with intrahypothalamic liraglutide administration compared with
the control group (Figure 4a and b). We observed no changes in
gene expression patterns in iBAT (Figure 4c) after intrahypotha-
lamic liraglutide treatment. The subcutaneous liraglutide treat-
ment did not affect expression of thermogenic and browning
markers (Supplementary Material).
Central chronic liraglutide treatment increases circulating plasma
thyroxine levels
Chronic intrahypothalamic liraglutide treatment led to a 1.4-fold
increase in circulating concentrations of the thyroid hormone
thyroxine (T4) on day 28 compared with the control group
(Po0.05; Table 1). Circulating thyroid-stimulating hormone levels
were unaffected by chronic intrahypothalamic and subcutaneous
liraglutide treatment compared with control group at treatment
day 21 (Table 1). Neither intrahypothalamic nor subcutaneous
liraglutide administration affected circulating thyroid-stimulating
hormone levels. Neither intrahypothalamic liraglutide nor sub-
cutaneous liraglutide treatment affected any circulating factor of
glucose metabolism (insulin, glucose) or fatty acid and lipid
metabolism (leptin, NEFA, free glycerol, triglyceride).
Central chronic liraglutide treatment activates the hypothalamic
melanocortin system
Chronic intrahypothalamic administration of liraglutide led to an
18-fold induction of the hypothalamic melanocortin 4 receptor
gene (mc4r) compared with the control group (Po0.01; Figure 5)
but no further changes were found in any genes regulating food
intake and satiety in the hypothalamus (pomc, bdnf, agrp, npy, lepr,
pc1, glp1r). Expression of appetite regulating peptide α-msh was
undetectable. Expression of genes of the pituitary–thyroid axis
(tsh, trh, dio2) was likewise unaffected by intrahypothalamic
liraglutide treatment (Figure 5).
DISCUSSION
This study aimed to identify differential effects of chronic central
and peripheral liraglutide treatment. Central application of
liraglutide induced a significant body weight loss and overall
reduction in body weight gain, which was supported by a
significant loss of adipose tissue mass and reduction in visceral
adipose tissue gain. Furthermore, chronic intrahypothalamic
liraglutide treatment led to a significant activation of hypotha-
lamic mc4r gene expression and a significant increase in plasma
T4 concentrations.
A significant reduction of body weight gain during the first
16 days of intrahypothalamic liraglutide treatment was observed.
The body weight remained lower in the liraglutide-treated group
during the last week of treatment. We found that intrahypotha-
lamic liraglutide treatment induced a significant body weight loss
from day 9 to day 28 and a significant loss in adipose tissue
depots (iWAT, iBAT) after 28 days compared with subcutaneous
liraglutide treatment. This is the first study on chronic intrahy-
pothalamic treatment in animal trials but the acute studies
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(24 h to 6 days) showed similar effects on body weight.5,15,16 In
contrast to acute rat studies with central liraglutide
administration,17,18 we showed that chronic (28 days) rather than
acute (24 h) intrahypothalamic liraglutide treatment led to a
reduction in body weight gain (Supplementary Material). The body
weight regain at the end of our study (28 days) could be caused
by GLP-1 receptor desensitization (tachyphylaxis) on continuous
stimulation19 supported by the unchanged GLP-1R expression in
the hypothalamus in our study after chronic intrahypothalamic
liraglutide administration. Other physiological mechanisms such
as reduced energy expenditure, increased appetite seen as an
increase in ghrelin,20 reduced satiety or a reduction in plasma
Figure 1. Central IH administration of liraglutide leads to reduced overall body weight gain and adipose tissue mass reduction. (a) Reduced
body weight gain over 28 days triggered by continuous IH administration of liraglutide (IH 10 μg per day) compared with the corresponding
control group (vehicle, aCSF) interaction P= 0.0025, time Po0.0001, treatment Po0.0210. (b) Reduced adipose tissue weights from eWAT,
iWAT and iBAT depots after 28 days of IH liraglutide administration. (c) No change in body weight from baseline to day 28 triggered by
continuous SC administration of liraglutide (200 μg kg− 1 per day) compared with corresponding control group (vehicle, 0.9% sNaCl)
interaction P= 0.3379, time Po0.0001, treatment P= 0.0295. (d) No change in adipose tissue weights from eWAT, iWAT and iBAT depots after
28 days of SC liraglutide administration. (e) Reduced body weight over 28 days after chronic IH liraglutide treatment compared with SC
liraglutide treatment. Interaction P= 0.0010, time Po0.0001, treatment P= 0.0024. (f) Reduced adipose tissue weights from eWAT, iWAT, iBAT
after 28 days of IH liraglutide versus SC liraglutide administration. Data are given as mean± s.d. of seven to eight animals per group. (*Po0.05,
**Po0.01, #Po0.001). IH, intrahypothalamic; SC, subcutaneous.
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leptin could be further explanations for the observed body weight
regain.21–24 As we investigated the liraglutide effects in a healthy
lean animal model without leptin resistance, an observed trend
towards reduced plasma leptin levels after chronic intrahypotha-
lamic treatment could be responsible for the body weight regain,
as this reduction has been suggested to increase caloric
intake.21,24 Thus, the body weight regain seems to be a natural
protective counter-regulatory physiological response after weight
loss, also seen in humans.3
In humans, 3 mg liraglutide causes a moderate weight loss of
6–8 kg in obese individuals with slight weight regain.3,4 Our
animal study did not result in any reduction in body weight gain
after subcutaneous chronic administration of liraglutide while
similar subcutaneous liraglutide treatment has led to anorectic
effects and body weight loss in diet-induced obese rats on high-
fat diet.8 A more pronounced anorectic effect can be expected in
such high-fat diet studies25,26 compared with our study design
with lean rats on normal diet with the primary aim to test
liraglutide effects in a healthy animal model.
Furthermore, the anorectic effect and body weight loss are
affected by the liraglutide dosing regimen,3,27,28 the maximum
dose of liraglutide used as obesity treatment is 3 mg, whereas
Figure 2. Central intrahypothalamic (IH) administration of liraglutide reduces the size of brown adipocytes. (a) Adipocyte size after 28 days of
liraglutide administration (IH 10 μg per day). (b) Representative hematoxylin and eosin (H&E) stainings of adipose tissues (eWAT, iWAT, iBAT)
28 days after IH liraglutide injection; × 20 magnification, scale bar, 200 μm. Data are given as mean+s.d. of seven to eight animals (*Po0.05).
Figure 3. Central intrahypothalamic (IH) administration of liraglutide reduces visceral adipose tissue volume gain. (a) μCT calculated visceral
adipose tissue (VAT) volume (mm3) at baseline (before treatment) and at day 28. (b) μCT calculated subcutaneous adipose tissue (SAT) volume
(mm3) change from baseline to day 28. (c) Fully segmented μCT images (xyz) of the abdominal region VAT (red) SAT (blue). Black/white images
show transverse axial μCT images of rat abdomen at level L5–S1 intervertebral disk. Data are given as mean+s.d. of seven to eight animals
(*Po0.05).
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1.2 mg or 1.8 mg are used for the treatment of type 2 diabetes.
Such high dosing is necessary to decrease the caloric intake and
reduce body weight compared with lower dosing, which is already
sufficient to increase insulin secretion and lower blood glucose
levels. Considering the measured liraglutide concentration in
plasma on day 28 (2000 pmol l−1 ± 975), we assume that the
continuous subcutaneous dosing of liraglutide in our study was
not effective enough to stimulate the hypothalamic GLP-1
receptor to trigger body weight loss compared with a more
effective bolus administration in other studies.8,28
Our combined results on body weight gain and adipose tissue
reduction indicate that liraglutide exerts its body weight-reducing
effects more potently via central rather than peripheral
mechanisms.
A recent 24 h study associated the acute administration of
liraglutide with increased thermogenesis in brown adipose tissue
and browning of white adipose tissue through the AMP-activated
protein kinase pathway in the ventromedial hypothalamus
independent of food intake.5 We found no significant changes
in gene expression levels regarding the brown adipocyte marker
ucp1, transcription factors for browning/beiging (prdm16,
ppargc1a), browning/beiging-enriched markers (cidea, cidec,
tnfrsf9, zic1, adrβ1) and browning/beiging activators (fgf21,
bmp7).29–33 Our study does not support the involvement of
increased thermogenic or browning capability in liraglutide-
induced weight loss but this could be due to differences in the
delivery site.5 Several animal and human studies have attributed
the weight-reducing effects mediated by GLP-1R agonists to
caloric intake rather than to increased energy expenditure6,8,34,35
but our study was not designed to address this difference in more
detail.
Figure 4. Central intrahypothalamic (IH) administration of liraglutide neither induces browning nor thermogenesis. (a) Relative mRNA levels
(fold changes) in eWAT in IH liraglutide treatment (28 days) compared with control group (vehicle, aCSF). (b) Relative mRNA levels (fold
changes) in iWAT of IH 28 days liraglutide treatment compared with control group (vehicle, aCSF). (c) Relative mRNA levels (fold changes) in
iBAT of IH 28 days liraglutide treatment compared with control group (vehicle, aCSF). Rpl4 and PPia were used as reference genes. Data are
given as mean+s.d. of seven to eight animals per group.
Table 1. Central IH administration of liraglutide increases circulating T4 concentration
IH vehicle IH liraglutide
(10 μg per day)
SC vehicle SC liraglutide
(200 μg kg− 1 per day)
FG (μmol ml− 1) 13.21± 2.94 13.43± 2.73 11.98± 1.54 11.39± 1.71
NEFA (μmol ml− 1) 14.67± 4.14 15.54± 5.4 15.85± 5.0 17.76± 5.77
TAG (μmol l− 1) 0.08± 0.02 0.08± 0.03 0.10± 0.03 0.10± 0.04
Leptin (ng ml− 1) 25.20± 14.0 14.96± 13.54 8.20± 5.74 8.18± 5.48
Insulin (ng ml− 1) 1.71± 0.61 1.23± 0.45 1.24± 0.57 1.07± 0.12
Glucose (mmol l− 1) 7.04± 0.33 7.29± 0.69 7.90± 0.63 6.56± 0.89
T3 (ng dl− 1) 24.35± 5.6 25.95± 7.3 24.99± 8.6 24.34± 7.8
T4 (ng dl− 1) 57.78± 8.2 80.61± 23.3* 61.0± 12.6 58.42± 14.8
TSH (ng ml− 1)
(treatment day 21)
1.20 ± 0.30a 1.12 ± 0.35a 1.75 ± 1.20a 1.20 ± 0.31a
Abbreviations: FG, free glycerol; NEFA, non-esterified fatty acids; T3, triiodothyronine; T4, thyroxine; TAG, triglyceride; TSH, thyroid-stimulating hormone. aTSH
levels are only measured for day 21 due to lack of samples. Circulating plasma levels of markers for glucose metabolism (glucose, insulin), lipid metabolism
(leptin, NEFA, TAG, FG) and thyroid hormones (T3, T4) at day 28 after chronic intrahypothalamic (IH; 10 μg per day) and subcutaneous (SC; 200 μg kg− 1
per day) liraglutide treatment. Data are given as mean± s.d. of seven to eight animals per group (*Po0.05). Italic values are indicate a different time point of
TSH measurements compared to the other plasma hormone levels.
Figure 5. Central intrahypothalamic (IH) liraglutide administration
induces hypothalamic MC4R activation. Relative mRNA expression
levels (fold changes) of genes involved in pituitary–thyroid axis (tsh,
trh, dio2) and energy homeostasis (pomc, bdnf, agrp, npy, lepr, pc1, glp1r,
mc3r, mc4r) in the hypothalamus. Rplp0 was used as reference gene.
Data are given as mean+s.d. of seven to eight animals per group
compared with their corresponding control group (**Po0.01).
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Similar to the reduction in body weight gain, the chronic
intrahypothalamic liraglutide treatment in our study led to a
sustained reduction of eWAT and iWAT mass as well as a reduced
gain in visceral adipose tissue volume, but we found no such
effect after subcutaneous liraglutide administration. White adipo-
cytes showed a trend towards reduced size in eWAT and iWAT
after intrahypothalamic liraglutide administration. IBAT mass was
unaffected, whereas iBAT adipocytes were significantly reduced in
size after chronic intrahypothalamic liraglutide treatment. A
previous study using acute liraglutide treatment in diet-induced
obese mice attributed a 14-day fat mass reduction to central
GLP-1 receptor signaling,6 which supports our assumption that the
reduction in visceral adipose tissue is mainly mediated by
hypothalamic neural mechanisms as indicated by the clear
difference between the effects of intrahypothalamic and sub-
cutaneous liraglutide administration found in our study.
Hormonal parameters for glucose metabolism and fatty acid
metabolism were largely unaffected by chronic intrahypothalamic
liraglutide treatment except a significant increase in circulating T4
concentrations. In humans, weight loss and maintenance of body
weight have been associated with increased peripheral conversion
of T4 to the bioactive enantiomer reverse T323,36 but we found no
changes in the expression of type II iodothyronine deiodinase
(DIO2) in iBAT (data not shown), which is required for the
intracellular conversion of T4 to T3.37
We also tested the effect of chronic intrahypothalamic
liraglutide administration on neuronal centers known to regulate
caloric intake and energy homeostasis. In contrast to other studies,
we observed no change in the hypothalamic mRNA content of
orexigenic (agrp) or anorexigenic (pomc) neurons, but we found a
significant 18-fold induction of mc4r mRNA in the hypothalamus
after 28 days of intrahypothalamic liraglutide administration.
These results indicate an alternative pathway for liraglutide to
activate the anorectic MC4R was besides the previously described
POMC/CART produced melanocyte-stimulating hormone α-MSH
signaling in the hypothalamus.38–40 To our knowledge, we are first
to show that continuous, chronic liraglutide administration in the
hypothalamus leads to a significant activation of the MC4R.
Recently, a 5-day combination therapy including the MC4R
agonist RM-493 and liraglutide in diet-induced obese mice
showed improved body weight and fat mass reduction compared
with monotherapy.41 There is also evidence that the melanocortin
signaling is involved in the reward system,42 which was previously
reported as high-fat fed or candy-fed rats prefer low-fat or chow
diet after the administration of MC4R agonists (MTII).43,44
We conclude that continuous chronic intrahypothalamic
liraglutide treatment rather than peripheral administration leads
to an improvement in terms of reduced body weight and adipose
tissue weight and unchanged metabolic regulators. The activation
of the anorectic MC4R mechanism shows that liraglutide is a
potent regulator of energy homeostasis and that there is an
alternative pathway to stimulate the melanocortin system other
than POMC/α-MSH. Identification of novel anorectic targets in the
hypothalamus triggering the melanocortin system and its down-
stream system can help to develop safe low-dose combination
therapies to reduce side effects and improve the chronic response
and metabolic control.
Follow-up studies will help to disclose new targets linking the
melanocortin and thyroid systems responsible for the chronic
effects of liraglutide and consequently new therapies for obesity
treatment.
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